Stroke risk and NSAIDs: an Australian population-based study

被引:39
作者
Caughey, Gillian E. [1 ]
Roughead, Elizabeth E. [1 ]
Pratt, Nicole [1 ]
Killer, Graeme [2 ]
Gilbert, Andrew L. [1 ]
机构
[1] Univ S Australia, Sansom Inst, Qual Use Med & Pharm Res Ctr, Adelaide, SA 5001, Australia
[2] Dept Vet Affairs, Canberra, ACT, Australia
基金
澳大利亚研究理事会;
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK; CYCLO-OXYGENASE-2; INHIBITORS; GASTROINTESTINAL TOXICITY; BLOOD-PRESSURE; CYCLOOXYGENASE; METAANALYSIS; ROFECOXIB;
D O I
10.5694/mja11.10055
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective: To determine the risk of stroke associated with non-steroidal 1 anti-inflammatory drug (NSAID) use. Design, setting and participants: Retrospective cohort study of 162 065 Australian veterans with incident dispensing of an NSAID between 1 January 2001 and 31 December 2008, using prescription event sequence symmetry analysis. Main outcome measures: Hospitalisation for stroke, ischaemic stroke or haemorrhagic stroke. Results: The absolute risk of stroke was low: 7.1/1000 people/year. Incident use of NSAIDs was associated with a 1.88 times increased risk (95% CI, 1.70-2.08) of hospitalisation for stroke (ischaemic or haemorrhagic) following first ever dispensing of an NSAID. This equates to an increased absolute risk of 13.4 strokes/1000 people/year. Significant positive associations between starting an NSAID and having a hospitalisation for stroke were found for most NSAIDs, with adjusted sequence ratios ranging from 1.44 (95% CI, 1.16-1.80) for indomethacin to 1.80 (95% CI, 1.59-2.04) for rofecoxib. Conclusions: Incident use of NSAIDs was associated with an increased risk of stroke. Increased awareness of the potential for serious adverse cardiovascular events, together with individual assessment of cardiovascular risk, careful deliberation of the balance between risk and benefits and appropriate supervision, is required when initiating NSAID therapy.
引用
收藏
页码:525 / 529
页数:5
相关论文
共 35 条
[1]
[Anonymous], TREATM POP STAT Q RE
[2]
[Anonymous], 2010, INT STAT CLASS DIS R
[3]
[Anonymous], EUR SOC CARD C 2010
[4]
[Anonymous], AN THER CHEM COD CLA
[5]
*AUSTR GOV DEP HLT, 2009, AUSTR STAT MED 2008
[6]
Australian Government Department of Health and Ageing, 2011, SCHED PHARM BEN PBS
[7]
Australian Institute of Health and Welfare, 2002, HLTH CAR US COSTS CO
[8]
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[9]
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[10]
Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study [J].
Caughey, G. E. ;
Ramsay, E. N. ;
Vitry, A. I. ;
Gilbert, A. L. ;
Luszcz, M. A. ;
Ryan, P. ;
Roughead, E. E. .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2010, 64 (12) :1036-1042